옵션 체인은 다양한 행사가격과 만기일에 대한 Phathom Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Phathom Pharmaceuticals에 대한 시장 심리를 평가합니다..

Phathom Pharmaceuticals (NASDAQ:PHAT) 주식, 옵션 체인

Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals Inc

News

Guidance

Cummins Sees FY25 Revenue Down 2% To Up 3%, EBITDA Margin 16.2% To 17.2% Of Sales

These proactive actions will further reduce the Company's costs in response to ongoing market challenges, including global legislative and regulatory policy uncertainty. Specifically, ADM expects to achieve the majority of the cost savings on an annual run-rate basis through improvement in manufacturing costs, reduction in purchased materials and services, and targeted workforce reduction.&nbsp;

ADM Reveals Targeted Actions To Deliver $500M - $750M In Cost Savings Over Next 3 - 5 Years; Currently Expects Targeted Workforce Reduction Of 600 - 700 Roles Globally In 2025

Rosenblatt analyst Blair Abernethy maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Buy and maintains $204 price target.

Price Target

Analyst Ratings

Rosenblatt Maintains Buy on PTC, Maintains $204 Price Target

The dividend is payable on March 11, 2025 to shareholders of record on February 18, 2025. This is ADM's 93rd consecutive year of uninterrupted dividends.

Dividends

ADM Boosts Cash Dividend From $0.50 To $0.51 Per Share

Health Care

General

CPIX

Cumberland Pharmaceuticals Announces Advance Results From The Phase 2 FIGHT DMD Trial In Duchenne Muscular Dystrophy Heart Disease

Earnings

Earnings Beats

Earnings Misses

Cummins Q4 2024 GAAP EPS $3.02, Sales $8.447B Beat $8.071B Estimate

Northland Capital Markets analyst Michael Latimore maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Market Perform and raises the price target from $38 to $80.

PLTR

Northland Capital Markets Maintains Market Perform on Palantir Technologies, Raises Price Target to $80

Rosenblatt analyst Hans Mosesmann maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and maintains $250 price target.

Rosenblatt Maintains Buy on Advanced Micro Devices, Maintains $250 Price Target

Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) reported quarterly earnings of $4.10 per share which beat the analyst consensus estimate of $4.02 by 1.99 percent. This is a 11.11 percent increase over earnings of $3.69 per share from the same period last year. The company reported quarterly sales of $1.33 billion which missed the analyst consensus estimate of $1.41 billion by 5.48 percent. This is a 0.89 percent decrease over sales of $1.35 billion the same period last year.

HUBB

Hubbell Q4 2024 Adj EPS $4.10 Beats $4.02 Estimate, Sales $1.33B Miss $1.41B Estimate

ATI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.61 by 29.51 percent. This is a 23.44 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $1.20 billion which beat the analyst consensus estimate of $1.09 billion by 10.02 percent. This is a 12.78 percent increase over sales of $1.06 billion the same period last year.

ATI Q4 2024 Adj EPS $0.79 Beats $0.61 Estimate, Sales $1.20B Beat $1.09B Estimate

Simplify Asset Management launched the Simplify Currency Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXY#NYSE">FOXY</a>), an <a href="https://www.benzinga.com/etfs">actively managed fund</a> designed to benefit from foreign exchange market dynamics. The launch on Tuesday comes as global currency volatility rises, driven by Trump's push to weaken the dollar and uncertainty around tariffs.
In an interview with Benzinga, Managing Director, Portfolio Manager, and Emerging Markets Specialist at Simplify, Christopher Getter said, &#8220;There really isn't anything available to investors in the space, so in some sense, our ability to be original with a distinct product that is not an expression on the dollar, per se—although there are a handful of single currency products out there—motivated us.&#8221;
Also Read: <a href="https://www.benzinga.com/25/02/43438809/teucrium-expands-etf-offerings-with-yields-for-you-strategy-a-etf">Teucrium Expands ETF Offerings with Yields For You Strategy A ETF</a>
The new ETF employs two strategies to generate returns with minimal dependence on equities or bonds. The first strategy is an Emerging Markets carry trade, utilizing eight currency pairs, each benchmarked against the U.S. dollar. The fund will hold &#8220;long&#8221; positions in the four currencies offering the highest interest rates while &#8220;shorting&#8221; the four with the lowest rates. This strategy seeks to profit from yield differentials and currency fluctuations.
The second strategy takes six different pairs of G10 currencies. It involves taking &#8220;long&#8221; positions in the three currencies exhibiting the strongest yield momentum increases, while &#8220;shorting&#8221; the three with the weakest. The strategy benefits from the mean-reverting nature of G10 currencies, potentially lowering overall risk by combining lesser-correlated approaches across different markets. &#8220;This approach, which we have refined through a number of iterations, provided the best alpha and return potential,&#8221; Getter added.
The backdrop of global currency fluctuations makes FOXY's launch particularly timely. &#8220;Beyond the direct targets of tariffs like Mexico and China, we think the EM currencies can do well against the USD, which should provide a boost to performance,&#8221; said Getter.
The ETF also accounts for heightened FX volatility driven by geopolitical tensions and trade policies, such as the fresh batch of tariffs. &#8220;Without getting too deep into the specifics, we can scale our exposures at both the individual currency level as well as at the overall portfolio level to either take advantage of volatility or to adopt more of a defensive posture,&#8221; said Getter.
Amid policy uncertainty and geopolitical shifts, actively managed currency strategies like FOXY could offer investors an alternative way to diversify and hedge against volatile FX markets. &#8220;Correlations across traditional asset classes (think of a typical 60/40 mix) have risen, so we think there is a demand for uncorrelated asset classes and that this demand is becoming increasingly structural in nature,&#8221; Getter said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43440361/exclusive-dogecoin-etf-justified-more-meme-coins-etfs-possible-bitwise-cio-says">EXCLUSIVE: Dogecoin ETF Justified, More Meme Coins ETFs Possible, Bitwise CIO Says</a></li>
</ul>
Photo: Shutterstock

New ETFs

Interview

ETFs

Simplify Exchange Traded Funds Simplify Currency Strategy ETF

FOXY

Simplify Launches FOXY ETF To Navigate FX Volatility, Tariff Uncertainty

Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) reported quarterly earnings of $1.14 per share which missed the analyst consensus estimate of $1.15 by 0.87 percent. This is a 16.18 percent decrease over earnings of $1.36 per share from the same period last year. The company reported quarterly sales of $21.50 billion which missed the analyst consensus estimate of $22.66 billion by 5.13 percent. This is a 6.44 percent decrease over sales of $22.98 billion the same period last year.

Archer-Daniels Midland Q4 2024 Adj EPS $1.14 Misses $1.15 Estimate, Sales $21.50B Miss $22.66B Estimate

The Trump (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) meme coin has plunged 42.6% in the past week, following Donald Trump's tariff announcement—a sharp reversal for the <a href="https://www.benzinga.com/money/trump-coin-price-prediction">high-flying meme crypto</a>.
What Happened: According to Lookonchain, a whale who had pocketed $11.8 million in TRUMP gains in mid-January reinvested his profits, only to see the trade turn against him. 
The whale spent $33.9 million to acquire 766,083 TRUMP at an average price of $44.25, only to suffer a $21 million loss as prices collapsed. 
This move <a href="https://x.com/lookonchain/status/1886704116652810567">erased</a> not only their entire profit but also $9 million of the original capital.
Despite this steep drop, data from Merkle Science and Chainalysis, cited by Reuters, shows TRUMP having generated $100 million in trading fees in less than two weeks, highlighting continued high-volume activity.
Once the best-performing meme coin before the tariff news, TRUMP has now lost nearly 50% of its total valuation in just days.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43430801/exclusive-anthony-scaramucci-warns-donald-trumps-crypto-promises-may-be-a-mirage">EXCLUSIVE: Anthony Scaramucci Warns Donald Trump&#8217;s Crypto Promises May Be A &#8216;Mirage&#8217;</a>
What's Next: Trader Johnny believes buying TRUMP under $20 will be seen as a bargain in the coming months, predicting that it will ultimately reach new all-time highs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I think buying <a href="https://twitter.com/search?q=%24TRUMP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TRUMP</a> sub $20 will be looked as a steal a few months from now Expecting this to go to new ATH&#39;s at some point <a href="https://t.co/6DDkqvUoUf">pic.twitter.com/6DDkqvUoUf</a>
&mdash; Johnny (@CryptoGodJohn) <a href="https://twitter.com/CryptoGodJohn/status/1886434777340739764?ref_src=twsrc%5Etfw">February 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Rodney, another crypto trader, <a href="https://x.com/cryptojourneyrs/status/1886425944942113031">notes</a> that despite the crash, TRUMP still holds the fourth position among meme coins, urging investors to stay patient for a recovery.
Trader Viktor <a href="https://x.com/thedefivillain/status/1886712178654503130">argues</a> that while the TRUMP and MELANIA meme coins were attractive short hedges, the risk/reward dynamics have now shifted.
He describes TRUMP as a low beta bleeding coin with many underwater bagholders, but also points out that liquidity is so thick that volatility has decreased.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43390075/department-of-government-efficiency-meme-coin-plummets-30-as-attention-pivots-to-trump">Department Of Government Efficiency Meme Coin Plummets 30% As Attention Pivots To TRUMP</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$TRUMP

TRUMP Meme Coin Down 42% In A Week: How Low Can It Go?

Rosenblatt analyst Kevin Cassidy maintains Synaptics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) with a Buy and maintains $92 price target.

SYNA

Rosenblatt Maintains Buy on Synaptics, Maintains $92 Price Target

Financing

ACON

Aclarion Secures Funding For Its CLARITY Trial For Nociscan

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) with a Outperform and lowers the price target from $318 to $294.

Keefe, Bruyette & Woods Maintains Outperform on RenaissanceRe Holdings, Lowers Price Target to $294

Rosenblatt analyst Mike Genovese maintains Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) with a Buy and raises the price target from $280 to $285.

Rosenblatt Maintains Buy on Fabrinet, Raises Price Target to $285

Rosenblatt analyst Kevin Cassidy maintains Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with a Buy and raises the price target from $85 to $92.

RMBS

Rosenblatt Maintains Buy on Rambus, Raises Price Target to $92

Baird analyst Eric Coldwell maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Neutral and lowers the price target from $15 to $14.

Baird Maintains Neutral on Owens & Minor, Lowers Price Target to $14

Additionally, the Company expects its financial performance for each of the remaining measures that it previously issued guidance for to be at or above the high-end of the previously announced ranges.

GETY

Getty Images Expects Q4 Revenue Of $244M - $250M (Est $244.99M), Revises 2024 Revenue Outlook From $934M - $943M To $936M - $942M (Est $937.01M)

Catalyst Watch: November jobs, OPEC+ meeting, Marvell, Salesforce earnings

Salesforce, Marvell Technology, And Kroger Report As Earnings Season Slowing To A Crawl

Phathom Pharmaceuticals (PHAT) announced it has submitted a Citizen Petition, CP, with the U.S. Food and Drug Administration, FDA. The petition for...

Phathom Pharmaceuticals submits Citizen Petition to FDA

Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of $28.00....

Phathom Pharmaceuticals: Undervalued Opportunity with Strategic Moves for Extended Exclusivity

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report), with...

Phathom Pharmaceuticals: Securing Long-term Exclusivity for Growth Potential

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report). The ...

Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)

Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.

Top Biotech Short Squeeze Stocks

Optimistic Outlook on Phathom Pharmaceuticals: Buy Rating Amid Market Undervaluation

Needham's top stocks for 2025: AX, CYBR, CART and more

ABBV

ACVA

ALGM

AMZN

ATSG

AXSM

CAKE

CART

CELH

CHWY

CRDO

CRVO

CSGP

CTLT

CYBR

DAVA

DECK

DLTR

DOCU

FIVE

FLYE

GALT

GAUZ

GTLB

HIMS

HOOD

IMPP

JANX

KIRK

KLAC

LITE

LQDA

LULU

MKFG

MRVL

MTEM

NAMI

NNDM

NVDA

OKTA

ONTO

PHAT

PSTG

PSTX

QCOM

RAPP

RILY

ROKU

SAVA

SCWX

SGHC

SHAK

SLAB

SNPS

SOFI

TENB

TSCO

TSHA

ULTA

VALE

VRNT

Press Releases

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Comments

Phathom Pharmaceuticals

Phathom Pharmaceuticals (PHAT) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌